Document is current

Article History

Accepted: 20 January 2025

First Online: 4 February 2025

Declarations

:

: No external funding was used in the preparation of this article.

: D.B. declares that they have no conflicts of interest that might be relevant to the contents of this article. J.S. is a consultant for Janssen. S.H.I.O reports consulting fees from AnHeart Therapeutics, Pfizer, Janssen, Daiichi Sankyo, BMS, Merus and Avistone, honoraria from Dava Oncology, OncLive and Caris, is on the DSMB for Elevation Oncology and AnHeart, as well as stock/stock options from MBrace Therapeutics, BlossomHill Therapeutics, Elevation Oncology, Turning Point Therapeutics, Nuvalent, Lilly and Nuvation Bio. M.N. is on the advisory board for AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Janssen, Pfizer, Eli Lilly and Company, Bayer, Regeneron, BMS and Genentech; consultant for Caris Life Sciences (virtual tumor board); speaker for Blueprint Medicines, Janssen, Mirati and Takeda; and reports travel support from AnHeart Therapeutics. Reports stock/stock options from MBrace Therapeutics. Furthermore, M.N. is an Editorial Board member of Targeted Oncology. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: DB drafted the manuscript. JS drafted the manuscript and provided clinical interpretation. SHIO provided clinical interpretation and oversight. MN conceptualized the project and provided final review. All authors reviewed the final version of the manuscript.